tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

HALO Stock Latest News

Johnson & Johnson’s Darzalex with Halozyme’s Enhanze granted EU approval
The FlyJohnson & Johnson’s Darzalex with Halozyme’s Enhanze granted EU approval
7d ago
JNJ
HALO
EC approves subcutaneous RYBREVANT in combination with LAZCLUZE
PremiumThe Fly
EC approves subcutaneous RYBREVANT in combination with LAZCLUZE
9d ago
HALO
Halozyme: Bristol Myers receives positive CHMP opinion for Opdivo/Enhanze
PremiumThe Fly
Halozyme: Bristol Myers receives positive CHMP opinion for Opdivo/Enhanze
16d ago
BMY
HALO
Halozyme Announces Retirement of Chief Technical Officer
PremiumCompany Announcements
Halozyme Announces Retirement of Chief Technical Officer
25d ago
8K
HALO
Buy Rating for Halozyme: Potential Revenue Boost from Patent Dispute and Licensing Opportunities
PremiumRatings
Buy Rating for Halozyme: Potential Revenue Boost from Patent Dispute and Licensing Opportunities
1M ago
HALO
Buy Rating for Halozyme: Strategic Positioning and Intellectual Property Strengths Amid Patent Dispute
PremiumRatingsBuy Rating for Halozyme: Strategic Positioning and Intellectual Property Strengths Amid Patent Dispute
1M ago
HALO
Buy Rating for Halozyme: Potential Royalty Gains from Merck’s Keytruda and Strong Patent Position
Premium
Ratings
Buy Rating for Halozyme: Potential Royalty Gains from Merck’s Keytruda and Strong Patent Position
1M ago
HALO
Merck (MRK) Battling to Protect Key Cancer Drug as Patent Row Heats Up
Premium
Market News
Merck (MRK) Battling to Protect Key Cancer Drug as Patent Row Heats Up
1M ago
MRK
HALO
Merck’s Keytruda subject of brewing patent dispute with Halozyme, WSJ says
PremiumThe Fly
Merck’s Keytruda subject of brewing patent dispute with Halozyme, WSJ says
1M ago
MRK
HALO
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
2M ago
ADTX
ARDX
Halozyme price target raised to $60 from $57 at Wells Fargo
PremiumThe Fly
Halozyme price target raised to $60 from $57 at Wells Fargo
2M ago
HALO
Halozyme Therapeutics: Record Earnings and Future Growth
PremiumCompany Announcements
Halozyme Therapeutics: Record Earnings and Future Growth
2M ago
HALO
Halozyme price target raised to $78 from $73 at Citizens JMP
PremiumThe FlyHalozyme price target raised to $78 from $73 at Citizens JMP
2M ago
HALO
Buy Rating Affirmed: Halozyme’s Robust Growth and Strategic Positioning Drive Positive Outlook
Premium
Ratings
Buy Rating Affirmed: Halozyme’s Robust Growth and Strategic Positioning Drive Positive Outlook
2M ago
HALO
Halozyme price target raised to $72 from $70 at H.C. Wainwright
Premium
The Fly
Halozyme price target raised to $72 from $70 at H.C. Wainwright
2M ago
HALO
Halozyme Therapeutics Achieves Record Revenue in 2024
PremiumCompany Announcements
Halozyme Therapeutics Achieves Record Revenue in 2024
2M ago
HALO
Positive Outlook and Strategic Growth: Brendan Smith’s Buy Rating on Halozyme
PremiumRatings
Positive Outlook and Strategic Growth: Brendan Smith’s Buy Rating on Halozyme
2M ago
HALO
Halozyme reports Q4 EPS $1.06, consensus $1.16
PremiumThe Fly
Halozyme reports Q4 EPS $1.06, consensus $1.16
2M ago
HALO
Halozyme backs FY25 EPS view of $4.95-$5.35, consensus $5.05
PremiumThe Fly
Halozyme backs FY25 EPS view of $4.95-$5.35, consensus $5.05
2M ago
HALO
Halozyme reports Q4 non-GAAP EPS $1.26, consensus $1.16
PremiumThe FlyHalozyme reports Q4 non-GAAP EPS $1.26, consensus $1.16
2M ago
HALO
HALO Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
HALO Upcoming Earnings Report: What to Expect?
2M ago
HALO
Halozyme assumed with an Overweight at Morgan Stanley
Premium
The Fly
Halozyme assumed with an Overweight at Morgan Stanley
2M ago
HALO

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >